Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

The molecular and cellular basis of corticosteroid resistance.

Chikanza IC, Kozaci D, Chernajovsky Y.

J Endocrinol. 2003 Dec;179(3):301-10. Review.

2.
3.

The differential expression of corticosteroid receptor isoforms in corticosteroid-resistant and -sensitive patients with rheumatoid arthritis.

Kozaci DL, Chernajovsky Y, Chikanza IC.

Rheumatology (Oxford). 2007 Apr;46(4):579-85. Epub 2006 Oct 13.

PMID:
17043048
5.

Corticosteroids: the drugs to beat.

Barnes PJ.

Eur J Pharmacol. 2006 Mar 8;533(1-3):2-14. Epub 2006 Jan 24. Review.

PMID:
16436275
6.
7.

Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway.

Liu FL, Chen CH, Chu SJ, Chen JH, Lai JH, Sytwu HK, Chang DM.

Rheumatology (Oxford). 2007 Aug;46(8):1266-73. Epub 2007 Jun 14.

PMID:
17569750
11.

Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway.

Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N, Song Y, Deng X.

Fundam Clin Pharmacol. 2009 Aug;23(4):449-55. doi: 10.1111/j.1472-8206.2009.00684.x. Epub 2009 May 6.

PMID:
19453757
12.

Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.

Vergne-Salle P, Léger DY, Bertin P, Trèves R, Beneytout JL, Liagre B.

Cytokine. 2005 Sep 7;31(5):335-48.

PMID:
16099671
13.

Diarctigenin, a lignan constituent from Arctium lappa, down-regulated zymosan-induced transcription of inflammatory genes through suppression of DNA binding ability of nuclear factor-kappaB in macrophages.

Kim BH, Hong SS, Kwon SW, Lee HY, Sung H, Lee IJ, Hwang BY, Song S, Lee CK, Chung D, Ahn B, Nam SY, Han SB, Kim Y.

J Pharmacol Exp Ther. 2008 Nov;327(2):393-401. doi: 10.1124/jpet.108.140145. Epub 2008 Aug 11.

15.

A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.

Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, Hepperle M, Harriman G, Jaffee BD, Ocain TD, Xu Y.

J Pharmacol Exp Ther. 2006 Jun;317(3):989-1001. Epub 2006 Mar 8.

16.
17.

Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors.

Newton R, Holden NS, Catley MC, Oyelusi W, Leigh R, Proud D, Barnes PJ.

J Pharmacol Exp Ther. 2007 May;321(2):734-42. Epub 2007 Feb 22.

18.

Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro.

Kuldo JM, Westra J, Asgeirsdóttir SA, Kok RJ, Oosterhuis K, Rots MG, Schouten JP, Limburg PC, Molema G.

Am J Physiol Cell Physiol. 2005 Nov;289(5):C1229-39. Epub 2005 Jun 22.

20.

CT20126, a novel immunosuppressant, prevents collagen-induced arthritis through the down-regulation of inflammatory gene expression by inhibiting NF-kappaB activation.

Lee SJ, Nam WD, Na HJ, Cho YL, Ha KS, Hwang JY, Lee H, Kim SO, Kwon YG, Kim YM.

Biochem Pharmacol. 2008 Jul 1;76(1):79-90. doi: 10.1016/j.bcp.2008.04.006. Epub 2008 Apr 18.

PMID:
18513703

Supplemental Content

Support Center